Tuesday, January 26, 2021

3 OTCs With UP To 500% Gain Potential Short Term: Enzolytics Inc. (ENZC), Electromedical Technologies, Inc. (EMED) and North America Frac Sand, Inc. (NAFS)

Must Read

With its Operational Subsidiary, Home Foam Corporation, UMAX Group Corp.(OTC: UMAX) is Taking The Foam Market By Storm

The polyurethane foam market is projected to reach USD 79.77 billion by 2023, at a CAGR of 8.0% between...

2 Technology Stocks To Light Up Your Portfolio This Year

KULR Technology Group, Inc. (OTCQB:KULR) develops, manufactures and licenses next-generation carbon fiber thermal management technologies for batteries and electronic...

As Life Becomes more and more Digitally Focused, these 4 Companies are Laying the Groundwork for Our Digital Future

As life becomes more and more digitally focused, cybersecurity becomes an increasingly important product on the market. Cybersecurity has...

Enzolytics, Inc. (OTC: ENZC) is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Immunotech is committed to creating drugs for the better health of mankind. Enzolytics is a 49% shareholder of IMMB BG.

Enzolytics’ flagship compound ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in the treatment of HIV/AIDS. IPF is the active drug substance of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has been shown to modulate the immune system.

Electromedical Technologies, Inc. (OTC: EMED) is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

Our animal studies do not involve any human testing, and are not related to our current products. We are conducting this research to augment and advance the science of electro-modulation in healthcare. The United States Food and Drug Administration has not reviewed or approved our animal research studies.

Goldman Small Cap Research Sets A $5.70 12-Month Price Target For Electromedical Technologies, Inc. (OTCQB: EMED) And Projects The Medical Device Company, Fo-cused On Chronic And Acute Pain Relief, Will Reach Volumes Of $1.55 Million In FY2021 And $17 Million In FY2022

Electromedical Technologies, Inc. (OTC: EMED) is poised to serve as a leading, broad- based chronic pain management bioelectronics provider. Leveraging its currently FDA-cleared flagship device that has a 10,000 unit installed base, EMED is set for clearance of a new device late next year that is smaller, cheaper, and with more capabilities including a telemedicine feature.

Bioelectronics is an important and developing field of “electronic” medicine which uses safe electrical impulses over the body’s neural circuitry to relieve pain, without drugs.

The Company’s innovative, affordable financial model also includes a novel telemedicine feature which, along with efficacy and ease of use, should drive new adoption. EMED’s recurring model includes a nominal down payment, monthly subscription fee, and a premium physician monitoring portal.

Our forecasts include 10,000 units sold upon introduction next year and a conservative 80,000 units sold in 2022, driving revenue to $17 million—which could prove to be conservative.

Even with a 12-month price target of $5.70, EMED’s shares are grossly undervalued. Our target is based on the low-end valuation of one of its comps in the peer group.

Voycare, Inc. (OTC: NAFS) is a California based telemedicine service provider and Chinese language digital health platform exclusively dedicated to women’s health in Asia, with the primary focus on China. Voycare is creating a new type of cross border health care experience for women by leveraging telehealth and the gig-economy, giving women a voice when making the right health care decision for themselves and their families. Voycare currently focuses on two important areas in women’s health, Counseling and Fertility. Founded in 2019, Voycare has offices in Los Angeles and Shanghai.

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -

Latest

With its Operational Subsidiary, Home Foam Corporation, UMAX Group Corp.(OTC: UMAX) is Taking The Foam Market By Storm

The polyurethane foam market is projected to reach USD 79.77 billion by 2023, at a CAGR of 8.0% between...

2 Technology Stocks To Light Up Your Portfolio This Year

KULR Technology Group, Inc. (OTCQB:KULR) develops, manufactures and licenses next-generation carbon fiber thermal management technologies for batteries and electronic systems. Leveraging the company's roots...

As Life Becomes more and more Digitally Focused, these 4 Companies are Laying the Groundwork for Our Digital Future

As life becomes more and more digitally focused, cybersecurity becomes an increasingly important product on the market. Cybersecurity has become an essential part of...

4 OTC Stocks with UP to 500% Upside Potential

Limitless Venture Group (OTC: LVGI) provides its shareholders with access to leading small and medium-sized businesses focused on growth. Leveraging its permanent capital base,...

5G Related Stocks To Consider For 2021: Qualcomm (QCOM), AmpliTech (AMPG) and Crown Castle (CCI)

Qualcomm (NASDAQ: QCOM) Snapdragon 888 chips will power top-end Android phones next year Qualcomm recently announced the Snapdragon 888, its new high-end chip with a...
- Advertisement -

More Articles Like This

- Advertisement -